Feature Articles
From Supplier to Public Health Player: The Changing Role of Biopharma Companies
Cell and gene therapies, collectively termed Advanced Therapy Medicinal Products (ATMPs) in the EU, ...
Physician Opinions About “Fair” Prices Vary for Certain Therapies
As the cost of pharmaceutical and biotechnology therapies continues to rise, concern about the ...
HyperPointe’s New CEO Helps Turn Airport Spas into COVID Testing Centers
When Ezra T. Ernst took over as the new Chief Executive Officer of HyperPointe ...
Moving Toward an Agile KAM Future
Physical access has been a growing challenge in life sciences as the number of ...
The Rush to Real-Time ROI: Pharma’s Quest for Conversions in a New COVID Reality
As the head of a data marketing and healthcare IT company, I’m no stranger ...
The Patient’s View: What Value Means to the Person Who Matters Most
Ultimately, patients have to be at the center of everything companies in the life ...
The Age of Anxiety—Tips to Alleviate Stress in the COVID-19 Workplace
Employees are more stressed now than at any other point in their professional careers. ...
- 2020
- Clinical Trials
- Commercialization
- Feature Articles
- HCPs
- July/August
- Marketing Strategy
- Medical Affairs
Working with Your Medical Affairs Team to Expedite Approval
As a marketer, it stands to reason you are keenly aware of the role ...
Q&A with Frank Jaeger, Chief Commercial Officer, Clarus Therapeutics
In March 2019, Clarus Therapeutics got exciting news. JATENZO, the first and only oral ...
The Ups and Downs of Medication Adherence During COVID-19
Just as people stockpiled toilet paper at the outset of our current global pandemic ...
Two Key Questions About Adherence/Compliance in 2020
PM360 asked experts who know how to improve medication adherence about the new challenges ...
10 New Solutions to Help Boost Medication Adherence
Medication nonadherence has long been a problem in the healthcare industry, but that issue ...
First Fill Buy Downs: Maximizing Return in the Face of Prior Authorization
There is no question that prior authorization (PA) requirements around prescribed branded and specialty ...
